• Mashup Score: 7
    How can neurotoxicity associated with CAR T-cell therapy in MM be managed? - 3 day(s) ago

    The Multiple Myeloma Hub spoke with Peter Forsberg, Colorado Blood Cancer Institute, Denver, US. We asked, How can neurotoxicity associated with CAR T-cell therapy in MM be managed?

    Source: multiplemyelomahub.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of MM_Hub
      MM_Hub

      The Multiple Myeloma Hub spoke with Peter Forsberg, @ColoradoBlood. We asked, How can neurotoxicity associated with CAR T-cell therapy in #MultipleMyeloma be managed? Watch here: https://t.co/XOhAsfe6C9 @ForsbergMD #myeloma #mmsm #MedEd https://t.co/OtFGcEszie

  • Mashup Score: 3
    Visual abstract | MonumenTAL-1: Long-term follow-up of talquetamab for the treatment of RRMM - 10 day(s) ago

    The Multiple Myeloma Hub presents a visual abstract of the phase I/II monumenTAL-1 study (NCT03399799), which evaluated the efficacy and safety of talquetamab, a GPRC5D-directed bispecific T-cell engager, for the treatment of patients with relapsed/refractory multiple myeloma.

    Source: multiplemyelomahub.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of MM_Hub
      MM_Hub

      In an extended follow-up of the phase I/II MonumenTAL-1 study, talquetamab continued to demonstrate durable responses in patients with relapsed/refractory #MultipleMyeloma with no new GPRC5D AE-related discontinuations. https://t.co/sn75P8Vx99 #mmsm #myeloma #MedEd https://t.co/Wenf6PDTmk

  • Mashup Score: 2
    Phase II GMMG-CONCEPT trial: Final analysis of Isa-KRd in patients with HR NDMM - 19 day(s) ago

    We summarize the final analysis of the transplant-eligible cohort of the phase II CONCEPT trial of Isa-KRd in patients with high-risk NDMM, which was presented by Lisa Leypoldt during the EHA 2025 Congress.

    Source: multiplemyelomahub.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of MM_Hub
      MM_Hub

      New data 📝 Final analysis of the CONCEPT trial presented by Lisa Leypoldt at #EHA2025 shows 74.8% of patients with transplant-eligible high-risk NDMM achieved MRD-negativity after consolidation with Isa-KRd. Learn more: https://t.co/uzOSy4QJ2X #MultipleMyeloma #myeloma https://t.co/Xopjm9gDSb

  • Mashup Score: 5
    First-in-human trial of JNJ-5322 in patients with RRMM: Preliminary phase I results - 28 day(s) ago

    We summarize key preliminary phase I results of the first-in-human trial of JNJ-5322 in patients with RRMM as presented by Rakesh Popat during the EHA 2025 Congress.

    Source: multiplemyelomahub.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of MM_Hub
      MM_Hub

      New data 📝 Preliminary phase I findings presented by Rakesh Popat at #EHA2025 show BCMA/GPRC5D-targeted BsAb JNJ-5322 is well tolerated with Grade 3–4 infections reported in 28.6% of patients with RRMM. Learn more: https://t.co/CreNWSxanw #MultipleMyeloma #myeloma #MedNews https://t.co/0u6f6IX3Cp

Load More